Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3‐ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline‐based induction/consolidation chemotherapy. Quizartinib is a select...

Descripción completa

Detalles Bibliográficos
Autores principales: Altman, Jessica K., Foran, James M., Pratz, Keith W., Trone, Denise, Cortes, Jorge E., Tallman, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586071/
https://www.ncbi.nlm.nih.gov/pubmed/29139135
http://dx.doi.org/10.1002/ajh.24974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586071/
https://www.ncbi.nlm.nih.gov/pubmed/29139135
http://dx.doi.org/10.1002/ajh.24974

Ejemplares similares